Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

"We are very excited to make this strategic investment in MediWound. It aligns with our strategy to bring radical innovations into the wound care space and provide alternative solutions to the more traditional debridement options to improve clinical outcomes and patient experience," said Zlatko Rihter, CEO of Mölnlycke. "This investment will support Mölnlycke's Wound Care mission to 'help free patients from the burden of wounds' and I look forward to this partnership."

Mölnlycke and MediWound have also entered into a collaboration agreement to strengthen their partnership. Under the key terms of this agreement, Mölnlycke is granted specific rights, including having a representative attend meetings of MediWound's R&D Committee and will also be able to participate in potential strategic partnership discussions and M&A processes under certain circumstances.

"We are delighted to have Mölnlycke's support. This substantial investment will empower us to strengthen our strategic plans, creating significant long-term value for our stakeholders and help to improve standards of care for patients" said Ofer Gonen, CEO of MediWound.

For more information, please conatct:
Jennifer Doak
Global Communications Director Wound Care
Email: [email protected]
Phone: +1 678 206 6179
Ellie Hanson
FINN Partners for MediWound
Email: [email protected]
Phone: +1 929 588 2008

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/molnlycke/r/molnlycke--health-care-announces-us--15m-investment-in-next-generation-enzymatic-therapeutics-compan,c4015001

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-announces-us-15m-investment-in-next-generation-enzymatic-therapeutics-company-mediwound-ltd-302196800.html